Congresses and Events
![](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-cardiology/intouch-newsletter/intouch-newsletter-q2-2017/congresses-and-events/_jcr_content/maincontent-par/image.img.intouch_nl_banner_en_1_645x175px_eu.jpg)
The SYNERGY™ Stent: complete revascularization solutions in complex PCI
![Webcast: The SYNERGY™ Stent: complete revascularization solutions in complex PCI](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-cardiology/intouch-newsletter/intouch-newsletter-q2-2017/congresses-and-events/_jcr_content/maincontent-par/image_0.img.intouch_newsletter_issue_5_topic_1_1_960x480px_eu.jpg)
In this Symposium from EuroPCR 2017, a panel of experts discuss about the recommended requirement for use of DES in clinical practice and the potential benefits of bioabsorbable polymer DES in high-bleeding risk patients. Watch the webcast and learn how the SYNERGY™ stent is being used in complex patient subsets.
LOTUS™ Valve: expanding treatment options in real-world practice
![Webcast: LOTUS™ Valve: expanding treatment options in real-world practice](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-cardiology/intouch-newsletter/intouch-newsletter-q2-2017/congresses-and-events/_jcr_content/maincontent-par/image_1.img.intouch_newsletter_issue_5_topic_1_2_960x480px_eu.jpg)
LOTUS™ Valve expands treatment options in real-world practice. From EuroPCR 2017, a webcast dedicated to the LOTUS™ program, reviewing a range topics from our trial data to some really good clinical examples.
Boston Scientific has closed Symetis Acquisition
![LOTUS™ Valve Platform and ACURATE TA™](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-cardiology/intouch-newsletter/intouch-newsletter-q2-2017/congresses-and-events/_jcr_content/maincontent-par/image_2.img.intouch_newsletter_issue_5_topic_1_3_960x480px_eu.jpg)
Boston Scientific Corporation has announced the close of its acquisition for $435 million of Symetis SA. With the completion of the acquisition, the Company will immediately begin selling the ACURATE TA™ and ACURATE neo™/TF™ valve systems, expanding its Structural Heart Portfolio and increasing the Offerings for the treatment of Patients with Valvular Heart Disease.